Sparrow Pharmaceuticals is developing targeted therapies for conditions of corticosteroid excess - associated with either the natural corticosteroid cortisol due to a tumor or long-term use of a corticosteroid drug such as prednisone. Sparrow's pipeline is led by SPI-62 in Phase 2 clinical development.
Location: United States
Employees: 1-10
Total raised: $145M
Founded date: 2013
Investors 4
| Date | Name | Website |
| 20.05.2021 | US Venture... | usvp.com |
| - | Puget Soun... | pugetsound... |
| - | OrbiMed | orbimed.co... |
| - | Slojo Inve... | slojoinves... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 24.09.2025 | Series B | $95M | - |
| 18.05.2021 | Series A | $50M | - |
Mentions in press and media 12
| Date | Title | Description |
| 24.09.2025 | Sparrow Pharmaceuticals Raises $95M in Series B Financing | Sparrow Pharmaceuticals, a Portland, OR-based cardiometabolic therapeutics company, raised $95M Series B financing. The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, Rive... |
| 24.09.2025 | Sparrow flies forward with $95M series B for midstage diabetes asset | Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of a $95 million series B, the company announced in a Sept. 24 release. The round was led by RA Capital Management and... |
| 24.09.2025 | Sparrow Pharmaceuticals Announces $95 Million Series B Financing | PORTLAND, OR, Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, announced the close of a $95 million Series B financing. >> Click here for more funding data on Sparrow Pharmaceuticals >> To export Sparro... |
| 24.09.2025 | Sparrow Pharmaceuticals Announces $95 Million Series B Financing to Advance Targeted Therapy for Type 2 Diabetes | - |
| 18.05.2021 | Sparrow Pharmaceuticals : Secures $50 Million Series A Financing | Sparrow Pharmaceuticals, an emerging clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced the closing of a $50 million Series A financing. OrbiMed led the inve... |
| 18.05.2021 | Sparrow Pharmaceuticals Secures $50 Million Series A Financing | - |
| 18.05.2021 | Sparrow Pharmaceuticals Secures $50 Million Series A Financing | - |
| 13.04.2016 | Day 2: INVEST 2016, live from Chicago | healthbox: the speed at which this whole industry is moving is incredbile, and the volumes of info are more than any one physician, health system can digest. it’s incredibly thoughtful integration of all these inputs. 1:40 PM: Watch MedHead... |
| 13.04.2016 | It’s official: Meet 4 of the country’s most impressive healthcare startups | A quartet of companies on Wednesday were selected among the 44 businesses that presented at MedCity INVEST, MedCity News’ healthcare investing conference this week in Chicago. The winning companies, honored as the Best of INVEST, are buildi... |
| - | Day 2: INVEST 2016, live from Chicago | Participate in the MedCity INVEST healthcare investing conference by watching parts of the event live online and following our Day 2 liveblog here. The schedule of live broadcasts is listed here and will be shown in this post as they happen... |
Show more